Products
Bleomycin Sulfate (mixture)

Appearance:White to yellow solid

Storage:Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months

Bleomycin Sulfate (mixture)
Cat.No:
IB0871
Brand:
Solarbio
SKU Tongzhou Beijing Haidian Beijing Wuhan Guangzhou
IB0871-10mg Inquiry Inquiry Inquiry Inquiry
IB0871-20mg Inquiry Inquiry Inquiry Inquiry
Qty:
-
+
Order now

It is a class of water-soluble alkaline glycopeptide antibiotics.It mainly inhibits the incorporation of thymidine into DNA, binds to DNA to destroy and decompose it, and acts on the S phase of the proliferating cell cycle. It can be used for resistance screening and induction of pulmonary fibrosis models.


Examples of using this product(for reference only):

In Vivo:

Mice(male ICR mice, aged 8–12 weeks,weighting 18–22 g;):

The pulmonary fibrosis model in mice was prepared by atomization inhalation of bleomycin. When the mice were awake, they were put into a transparent plexiglass box with 30 cm×30 cm×20 cm connected with the atomizer and atomized 5 g/L (50%) bleomycin diluent was sprayed into the box through the atomizer tube. Three to four mice were put in the box at a time and exposed to bleomycin for a total of 3 hours and 15 minutes of bleomycin inhalation separated by 7 sessions of 5 minutes of rest. In the control group, mice received saline as a replacement for bleomycin inhalation [4, 18]. On the second day after modeling, all mice except those in the control group and model group were orally treated with saline, and the mice in the positive group and treatment group were continuously administrated with prednisone acetate (at a dose of 0.0064 mg/g) or Bufei decoction (at a dose of 1.235 mg/g) for 4 weeks.

Abstract:

Objective:This study aimed to investigate the mechanistic action and therapeutic effects of Bufei decoction on idiopathic pulmonary fibrosis (IPF) after inhalation of bleomycin.

Methods:Pulmonary fibrosis model in mice was prepared by atomization inhalation of bleomycin. Then, the mice were randomly divided into five groups (control group, model group, positive group, and treatment group) and administrated the drugs for 4 weeks. H&E and Masson's staining of lung tissues were used to observe the morphological changes and deposition of fibers, and the degree of fibrosis was evaluated by hydroxyproline content. The expression and activation of NF-κB were determined by western blotting and immunohistochemistry. The infiltration of macrophages was detected by immunostaining of CD45 and F4/80 in lung tissues.

Results:In mouse IPF, Bufei decoction alleviated the pathological changes and the deposition of fibrosis by decreasing the content of hydroxyproline of lung tissues. The antipulmonary fibrosis might rely on the effects of preventing the infiltration of inflammatory cells and inhibiting the expression and activation of NF-κB in lung tissue.Conclusion: Bufei decoction improved the process of pulmonary fibrosis by regulating the activation and expression of the NF-κB signal transduction pathway, which provided a therapeutic option for IPF patients.

Reference:

Yang S, Cui W, Wang M, Xing L, Wang Y, Zhu P, Qu Q, Tang Q. Bufei Decoction Alleviated Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Mice by Anti-Inflammation. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. doi: 10.1155/2020/7483278. PMID: 32963571; PMCID: PMC7495219.

Remark:
These protocols are for reference only. Solarbio does not independently validate these methods.

Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Experimental Images
Mix
Yang S, et al. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. control group (control), bleomycin group (model), bleomycin + prednisone acetate group (positive), and bleomycin + Bufei decoction (treatment).
Yang S, et al. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. control group (control), bleomycin group (model), bleomycin + prednisone acetate group (positive), and bleomycin + Bufei decoction (treatment).
Yang S, et al. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. control group (control), bleomycin group (model), bleomycin + prednisone acetate group (positive), and bleomycin + Bufei decoction (treatment).
Yang S, et al. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. control group (control), bleomycin group (model), bleomycin + prednisone acetate group (positive), and bleomycin + Bufei decoction (treatment).
Yang S, et al. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. control group (control), bleomycin group (model), bleomycin + prednisone acetate group (positive), and bleomycin + Bufei decoction (treatment).
来源文献:Yang S, et al. Evid Based Complement Alternat Med. 2020 Sep 8;2020:7483278. control group (control), bleomycin group (model), bleomycin + prednisone acetate group (positive), and bleomycin + Bufei decoction (treatment).
SERVICE FOR SCIENTIFIC RESEARCH,RESPONSIBLE FOR LIFE
Contact Us
Address: No 85, Liandong U Valley, Middle Zone, 101102, Tongzhou Dist, Beijing, China
Tel: +86 010 50973105
Technical Support Email: service@solarbio.com
Purchaser Email: purchase@solarbio.com
Sales Email: sales@solarbio.com
Copyright © 2005-2021 Solarbio all rights reserved.
 ICP Filing Certificate京ICP备12051307号-7